94 related articles for article (PubMed ID: 2972906)
1. [Intratumoral administration of OK432 in rats with liver tumor].
Ishimaru M
Nihon Geka Gakkai Zasshi; 1988 Jun; 89(6):880-8. PubMed ID: 2972906
[TBL] [Abstract][Full Text] [Related]
2. [Immunomodulating effect of intratumoral (IT) injection of biological response modifiers (BRM) on tumor-bearing hosts].
Okuno K; Nakajima I; Shilayama Y; Hirohata T; Ohnishi H; Nakamura Y; Nakamura T; Yasutomi M
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1543-9. PubMed ID: 2230439
[TBL] [Abstract][Full Text] [Related]
3. [Immunological study on localized liver injection of immunopotentiator OK-432-- experimental studies in rats].
Takada T; Yasuda H; Uchiyama K; Hasegawa H
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2267-71. PubMed ID: 6333213
[TBL] [Abstract][Full Text] [Related]
4. [An immunological study on the effect of simultaneous intrahepatic injection of an immunomodulator (OK-432) and adriamycin--an experiment in rats].
Takada T; Yasuda H; Uchiyama K; Hasegawa H; Miura S; Asagoe T; Hanaue H; Shikata J
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2305-13. PubMed ID: 2934024
[TBL] [Abstract][Full Text] [Related]
5. [An experimental study on the induction of anti-tumor immunological activity after cryosurgery for liver carcinoma, and the effect of concomitant immunotherapy with OK432].
Hanawa S
Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):57-65. PubMed ID: 8437553
[TBL] [Abstract][Full Text] [Related]
6. Prevention of growth of metastases in rat liver by perioperative immunoactivation.
Yamashita R; Hiraoka T; Kamimoto I; Miyauchi Y
Cancer Res; 1986 Jun; 46(6):3138-41. PubMed ID: 3486044
[TBL] [Abstract][Full Text] [Related]
7. Profile of T-cell receptor V beta gene usage of cytotoxic T cells induced by intrapleural administration of a streptococcal preparation, OK432, in malignant effusions.
Miyahara E; Yamaguchi Y; Hihara J; Noma K; Toge T
J Exp Ther Oncol; 1996 Jul; 1(4):242-50. PubMed ID: 9414411
[TBL] [Abstract][Full Text] [Related]
8. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
9. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
Akimoto M; Nishihira T; Hirakawa H; Abe M; Ohuchi N; Mori S; Kumagai K
Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
[TBL] [Abstract][Full Text] [Related]
10. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
Ishida N; Saito M; Nanjo M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study on the effect of intratumoral administration of OK-432 on breast cancer--anti-tumor immune response at the site of local injection].
Hosokawa T
Nihon Geka Gakkai Zasshi; 1991 May; 92(5):577-86. PubMed ID: 1831533
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). II. Analysis of the cytotoxic lymphocytes induced by OK-432 injection into tumor-bearing F344 rats.
Fukui H; Reynolds CW
J Natl Cancer Inst; 1987 Nov; 79(5):1019-24. PubMed ID: 3500354
[TBL] [Abstract][Full Text] [Related]
13. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on the antitumor activity of regional lymph nodes during immunotherapy].
Kawata H
Nihon Geka Gakkai Zasshi; 1984 Nov; 85(11):1479-89. PubMed ID: 6521727
[TBL] [Abstract][Full Text] [Related]
15. The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells.
Kurosawa S; Harada M; Shinomiya Y; Terao H; Nomoto K
Cancer Immunol Immunother; 1996 Sep; 43(1):31-8. PubMed ID: 8917633
[TBL] [Abstract][Full Text] [Related]
16. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
17. Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells.
Uchida A; Micksche M
Int J Cancer; 1983 Jan; 31(1):1-5. PubMed ID: 6219961
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of autologous tumor killing activity of tumor-associated large granular lymphocytes by the streptococcal preparation OK432.
Uchida A
Methods Find Exp Clin Pharmacol; 1986 Feb; 8(2):81-4. PubMed ID: 2423823
[TBL] [Abstract][Full Text] [Related]
19. Successful adoptive immunotherapy with OK432-inducible activated natural killer cells in tumor-bearing mice.
Yamaue H; Tanimura H; Iwahashi M; Tsunoda T; Tani M; Inoue M
Biotherapy; 1990; 2(1):51-61. PubMed ID: 2400628
[TBL] [Abstract][Full Text] [Related]
20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
